Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy.

ABSTRACT:

Background

Current FDA-approved therapeutic options for patients with metastatic melanoma include dacarbazine, interleukin 2, ipilimumab, vemurafenib, dabrafenib, and trametinib, but long-term tumor regression using available agents remains out of reach for most patients. Adoptive cell transfer (ACT) with autologous tumor-infiltrating lymphocytes (TILs) has shown encouraging results in clinical trials, with evidence of durable ongoing complete responses in patients with advanced melanoma. Emerging techniques to engineer T-cell receptors (TCRs) or chimeric antigen receptors (CARs) using lymphocytes from peripheral blood may offer new tactics in ACT.

Methods

We reviewed the literature to provide a synopsis on the development and clinical trial results of ACT, as well as the fu

SUBMITTER: Phan GQ 

PROVIDER: S-EPMC6322197 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature